Proceedings · Session S-169 · filed November 19, 2026

Lab Technology & MethodsSession paper

Researchers propose 3 phases to speed 14-day CAR-T sterility testing

Researchers outlined three phases for faster sterility testing of single-batch CAR-T therapies, as the 14-day compendial result can arrive after infusion begins.

By Tom Whitfield3 min read686 words

Summary

  • USP <71> takes 14 days to return a sterility result, while fresh CAR-T products often need infusion within 24–72 hours.
  • Manufacturers may use interim culture results at around 48 hours for exceptional early release.
  • The proposed pathway has three phases: analytical qualification, parallel compendial testing and conditional release.
  • The facility panel would contain at least 20 organisms, including C. acnes, Gram-negative bacteria, fungi and slow-growing organisms.
  • Regulatory fragmentation exists among three agencies—the FDA, EMA and TGA—while real-world CAR-T validation data remain lacking.
Growing Apart: Culture-Based Sterility Test Alternatives
FigureGrowing Apart: Culture-Based Sterility Test Alternatives — shameersrk / pixabay

By Tom Whitfield

USP <71> takes 14 days to produce a sterility result, yet fresh CAR-T products often must reach patients within 24–72 hours, leaving the standard test unable to confirm sterility before infusion.

Athena Stathoulis, a researcher at the University of Melbourne in Australia, and colleagues examined current cell-therapy practices in a recent study before proposing a three-phase pathway to address that timing gap.

What makes the 14-day test a release bottleneck?

Regulators require biopharmaceutical products to undergo standardized analysis. Technicians culture product samples so any contaminating bacteria or fungi can grow enough for full identification. Bacterial contamination remains a constant risk: multi-step production, nutrient-rich aqueous cell cultures and raw materials all create entry points for microorganisms.

The mismatch depends on the manufacturing model. Producers of protein therapeutics and monoclonal antibodies often manufacture high volumes across multiple sequential batches, allowing long tests to fit inside the manufacturing lifecycle without interrupting market supply. Single-batch, patient-specific therapies have no comparable schedule buffer.

“The gold-standard sterility test for cell therapies, USP <71>, takes 14 days to give a result. Fresh CAR T products often have to be infused within 24–72 hours, so the product reaches the patient long before its sterility is confirmed,” Stathoulis said.

In practice, firms often release fresh CAR T products early under exceptional protocols based on interim culture results at around 48 hours. That timing gives quality teams an earlier signal, but it does not close the full 14-day testing window before administration.

The shortened detection window raises the chance of missing slow-growing organisms; full sterility confirmation may arrive only after infusion. Stathoulis links that sequence to clinical handling because vein-to-vein time is linked to outcomes.

Her study also separates sterility testing from other production steps. Leukapheresis, transduction and expansion can be optimized, but regulatory mandates, rather than biology, fix the incubation period. The fixed 14-day period therefore remains the rate-limiting step for point-of-care and decentralized CAR T manufacturing.

Which rapid methods could replace incubation?

Stathoulis identified three alternatives: ATP bioluminescence, solid-phase cytometry, and molecular assays that target conserved bacterial and fungal ribosomal RNA genes, 16S and 18S rRNA. Her review ranks the molecular assays as the most compelling option.

Her reason is operational: molecular assays do not depend on bacterial growth, eliminate the incubation step and can produce results within hours. For manufacturers, that could compress batch-release time from 14 days to hours, although the source gives no assay-specific turnaround figure.

What does the three-phase pathway require?

The review proposes a staged move toward alternatives rather than an immediate replacement of USP <71>. Its three phases are:

  • Phase 1 — analytical qualification.
  • Phase 2 — parallel testing alongside compendial methods.
  • Phase 3 — conditional release.

The proposal adds controls across the pathway:

  • Test against a facility-specific panel of at least 20 organisms, including the skin bacterium Cutibacterium acnes, Gram-negative bacteria, fungi and slow-growing organisms.
  • Use viability dyes and enrichment steps to reduce false-positive and false-negative risk.
  • Run compendial testing after infusion as a safety net.
  • Predefine what happens when rapid and compendial results disagree.

Can regulators adopt faster tests?

Adoption depends on how the FDA, EMA and TGA treat rapid methods. Stathoulis said: “The barriers to adopting rapid sterility methods are regulatory rather than analytical, and regulation can be reformed. The main obstacles are regulatory fragmentation between the FDA, EMA, and TGA, and a lack of real-world validation data in CAR T products.”

That assessment points to a validation gap, not a completed technology transfer. The article gives quality and R&D leaders no sample size, head-to-head accuracy or sensitivity, assay-specific turnaround, cost or implementation data for the three alternatives. It also does not identify who funded the study.

Any forecast that 14 days will become hours therefore describes a proposed pathway, not a validated operating standard. The proposal's next test is validation work that fills the real-world data gap and clarifies how the FDA, EMA and TGA will handle discordant results.

via sciencedirect.com (Original)

Filed under

  • car-t-therapy
  • sterility-testing
  • rapid-microbiological-methods
  • molecular-assays
  • cell-therapy-manufacturing
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

280 articles

References

  1. Stable Pools Move Biologics Off the Clone-First Path
  2. Three-Day CAR T Expansion Could Counter 30% Annual Therapy Waste
  3. Label-Free Electrical Signals Could Give Bioprocess Engineers Earlier Warnings of Failing Cultures
  4. Biologics Fill-Finish Tech Transfer Draws Operational Scrutiny
  5. Standardized Apheresis Would Fix Cell Therapy's Variability Problem

« Previous articleNext article »